Measuring cellular immunity to influenza: Methods of detection, applications and challenges

Vaccines

Volumn 3, Issue 2, 2015, Pages 293-319

  Coughlan, Lynda ^a   Lambe, Teresa ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cellular immunity; Immunity; Influenza; T cell

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INFLUENZA VACCINE; INTERLEUKIN 2; MATRIX PROTEIN; QUADRIVALENT INFLUENZA VACCINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS NUCLEOPROTEIN;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION ASSAY; CELLULAR IMMUNITY; CYTOTOXICITY ASSAY; DISEASE DURATION; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION ASSAY; HEMAGGLUTINATION INHIBITION; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; INTRACELLULAR CYTOKINE STAINING; MEDICAL PROCEDURES; MRNA EXPRESSION ASSAY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TETRAMER ASSAY; WHOLE BLOOD ASSAY;

EID: 85016872290     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines3020293     Document Type: Review

References (140)

1. Lambert, L.C.; Fauci, A.S. Influenza vaccines for the future. N Engl J Med 2010, 363, 2036–2044.
2. Molinari, N.A.; Ortega-Sanchez, I.R.; Messonnier, M.L.; Thompson, W.W.; Wortley, P.M.; Weintraub, E.; Bridges, C.B. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 2007, 25, 5086–5096.
3. Krammer, F.; Palese, P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013, 3, 521–530.
4. Margine, I.; Hai, R.; Albrecht, R.A.; Obermoser, G.; Harrod, A.C.; Banchereau, J.; Palucka, K.; Garcia-Sastre, A.; Palese, P.; Treanor, J.J.; et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J Virol. 2013, 87, 4728–4737.
5. Taubenberger, J.K.; Kash, J.C. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 2010, 7, 440–451.
6. Chen, R.; Holmes, E.C. Avian influenza virus exhibits rapid evolutionary dynamics. Mol Biol Evol. 2006, 23, 2336–2341.
7. McMichael, A.J.; Gotch, F.M.; Noble, G.R.; Beare, P.A. Cytotoxic T-cell immunity to influenza. N Engl J Med. 1983, 309, 13–17.
8. McCullers, J.A.; van de Velde, L.A.; Allison, K.J.; Branum, K.C.; Webby, R.J.; Flynn, P.M. Recipients of vaccine against the 1976 “swine flu” have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis. 2010, 50, 1487–1492.
9. Throsby, M.; van den Brink, E.; Jongeneelen, M.; Poon, L.L.; Alard, P.; Cornelissen, L.; Bakker, A.; Cox, F.; van Deventer, E.; Guan, Y.; et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLOS ONE 2008, 3, e3942.
10. Coughlan, L.; Mullarkey, C.; Gilbert, S. Adenoviral vectors as novel vaccines for influenza. J Pharm Pharmacol. 2015, doi:10.1111/jphp.12350.
11. Yewdell, J.W.; Schubert, U.; Bennink, J.R. At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. J Cell Sci. 2001, 114, 845–851.
12. Pamer, E.; Cresswell, P. Mechanisms of MHC class I—restricted antigen processing. Annu Rev Immunol. 1998, 16, 323–358.
13. Leone, P.; Shin, E.C.; Perosa, F.; Vacca, A.; Dammacco, F.; Racanelli, V. MHC class I antigen processing and presenting machinery: Organization, function, and defects in tumor cells. J Natl Cancer Inst. 2013, 105, 1172–1187.
14. Germain, R.N.; Margulies, D.H. The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993, 11, 403–450.
15. Weinfurter, J.T.; Brunner, K.; Capuano, S.V., 3rd; Li, C.; Broman, K.W.; Kawaoka, Y.; Friedrich, T.C. Cross-reactive T cells are involved in rapid clearance of 2009 pandemic H1N1 influenza virus in nonhuman primates. PLOS Pathog. 2011, 7, e1002381.
16. Valkenburg, S.A.; Rutigliano, J.A.; Ellebedy, A.H.; Doherty, P.C.; Thomas, P.G.; Kedzierska, K. Immunity to seasonal and pandemic influenza A viruses. Microbes Infect 2011, 13, 489–501.
17. Amsen, D.; Backer, R.A.; Helbig, C. Decisions on the road to memory. Adv Exp Med Biol. 2013, 785, 107–120.
18. Kreijtz, J.H.; Fouchier, R.A.; Rimmelzwaan, G.F. Immune responses to influenza virus infection. Virus Res. 2011, 162, 19–30.
19. Wu, C.; Zanker, D.; Valkenburg, S.; Tan, B.; Kedzierska, K.; Zou, Q.M.; Doherty, P.C.; Chen, W. Systematic identification of immunodominant CD8+ T-cell responses to influenza A virus in HLA-A2 individuals. Proc Natl Acad Sci USA 2011, 108, 9178–9183.
20. Shaw, M.L.; Stone, K.L.; Colangelo, C.M.; Gulcicek, E.E.; Palese, P. Cellular proteins in influenza virus particles. PLOS Pathog. 2008, 4, e1000085.
21. Topham, D.J.; Tripp, R.A.; Doherty, P.C. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol. 1997, 159, 5197–5200.
22. Hufford, M.M.; Kim, T.S.; Sun, J.; Braciale, T.J. Antiviral CD8+ T cell effector activities in situ are regulated by target cell type. J Exp Med. 2011, 208, 167–180.
23. Altenburg, A.F.; Rimmelzwaan, G.F.; de Vries, R.D. Virus-specific T cells as correlate of (cross-)protective immunity against influenza. Vaccine 2015, 33, 500–506.
24. Cerwenka, A.; Morgan, T.M.; Harmsen, A.G.; Dutton, R.W. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection. J Exp Med. 1999, 189, 423–434.
25. Hamada, H.; Garcia-Hernandez Mde, L.; Reome, J.B.; Misra, S.K.; Strutt, T.M.; McKinstry, K.K.; Cooper, A.M.; Swain, S.L.; Dutton, R.W. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol. 2009, 182, 3469–3481.
26. Belz, G.T.; Wodarz, D.; Diaz, G.; Nowak, M.A.; Doherty, P.C. Compromised influenza virus-specific CD8+-T-cell memory in CD4+-T-cell-deficient mice. J Virol. 2002, 76, 12388–12393.
27. Sun, J.C.; Bevan, M.J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300, 339–342.
28. Boyden, A.W.; Legge, K.L.; Waldschmidt, T.J. Pulmonary infection with influenza A virus induces site-specific germinal center and T follicular helper cell responses. PLOS ONE 2012, 7, e40733.
29. Hillaire, M.L.; Rimmelzwaan, G.F.; Kreijtz, J.H. Clearance of influenza virus infections by T cells: Risk of collateral damage? Curr Opin Virol. 2013, 3, 430–437.
30. Chang, J.T.; Wherry, E.J.; Goldrath, A.W. Molecular regulation of effector and memory T cell differentiation. Nat Immunol. 2014, 15, 1104–1115.
31. Shin, H.; Iwasaki, A. Tissue-resident memory T cells. Immunol Rev. 2013, 255, 165–181.
32. Liang, S.H.; Mozdzanowska, K.; Palladino, G.; Gerhard, W. Heterosubtypic immunity to influenza type-A virus in mice—Effector mechanisms and their longevity. J Immunol. 1994, 152, 1653–1661.
33. Purwar, R.; Campbell, J.; Murphy, G.; Richards, W.G.; Clark, R.A.; Kupper, T.S. Resident memory T cells (T(RM)) are abundant in human lung: Diversity, function, and antigen specificity. PLOS ONE 2011, 6, e16245.
34. Sun, J.; Braciale, T.J. Role of T cell immunity in recovery from influenza virus infection. Curr Opin Virol. 2013, 3, 425–429.
35. Laurie, K.L.; Carolan, L.A.; Middleton, D.; Lowther, S.; Kelso, A.; Barr, I.G. Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis. 2010, 202, 1011–1020.
36. Epstein, S.L. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: An experiment of nature. J Infect Dis. 2006, 193, 49–53.
37. Hillaire, M.L.; Vogelzang-van Trierum, S.E.; Kreijtz, J.H.; de Mutsert, G.; Fouchier, R.A.; Osterhaus, A.D.; Rimmelzwaan, G.F. Human T-cells directed to seasonal influenza A virus cross-react with 2009 pandemic influenza A (H1N1) and swine-origin triple-reassortant H3N2 influenza viruses. J Gen Virol. 2013, 94, 583–592.
38. Kreijtz, J.H.; de Mutsert, G.; van Baalen, C.A.; Fouchier, R.A.; Osterhaus, A.D.; Rimmelzwaan, G.F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol. 2008, 82, 5161–5166.
39. Tu, W.; Mao, H.; Zheng, J.; Liu, Y.; Chiu, S.S.; Qin, G.; Chan, P.L.; Lam, K.T.; Guan, J.; Zhang, L.; et al Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J Virol. 2010, 84, 6527–6535.
40. Greenbaum, J.A.; Kotturi, M.F.; Kim, Y.; Oseroff, C.; Vaughan, K.; Salimi, N.; Vita, R.; Ponomarenko, J.; Scheuermann, R.H.; Sette, A.; et al Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009, 106, 20365–20370.
41. Ge, X.; Tan, V.; Bollyky, P.L.; Standifer, N.E.; James, E.A.; Kwok, W.W. Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus. J Virol. 2010, 84, 3312–3319.
42. Wilkinson, T.M.; Li, C.K.; Chui, C.S.; Huang, A.K.; Perkins, M.; Liebner, J.C.; Lambkin-Williams, R.; Gilbert, A.; Oxford, J.; Nicholas, B.; et al Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012, 18, 274–280.
43. Sridhar, S.; Begom, S.; Bermingham, A.; Hoschler, K.; Adamson, W.; Carman, W.; Bean, T.; Barclay, W.; Deeks, J.J.; Lalvani, A. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013, 19, 1305–1312.
44. McElhaney, J.E.; Xie, D.; Hager, W.D.; Barry, M.B.; Wang, Y.; Kleppinger, A.; Ewen, C.; Kane, K.P.; Bleackley, R.C. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006, 176, 6333–6339.
45. Forrest, B.D.; Pride, M.W.; Dunning, A.J.; Capeding, M.R.; Chotpitayasunondh, T.; Tam, J.S.; Rappaport, R.; Eldridge, J.H.; Gruber, W.C. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol. 2008, 15, 1042–1053.
46. Beran, J.; Vesikari, T.; Wertzova, V.; Karvonen, A.; Honegr, K.; Lindblad, N.; van Belle, P.; Peeters, M.; Innis, B.L.; Devaster, J.M. Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis. 2009, 200, 1861–1869.
47. Jefferson, T.O.; Rivetti, D.; di Pietrantonj, C.; Rivetti, A.; Demicheli, V. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2007, doi:10.1002/14651858.CD001269.pub4.
48. De Jong, J.C.; Beyer, W.E.; Palache, A.M.; Rimmelzwaan, G.F.; Osterhaus, A.D. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 2000, 61, 94–99.
49. Jefferson, T.; Rivetti, A.; Harnden, A.; di Pietrantonj, C.; Demicheli, V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008, doi:10.1002/14651858. CD004879.pub3.
50. Jain, V.K.; Rivera, L.; Zaman, K.; Espos, R.A., Jr.; Sirivichayakul, C.; Quiambao, B.P.; Rivera-Medina, D.M.; Kerdpanich, P.; Ceyhan, M.; Dinleyici, E.C.; et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med 2013, 369, 2481–2491.
51. Heiny, A.T.; Miotto, O.; Srinivasan, K.N.; Khan, A.M.; Zhang, G.L.; Brusic, V.; Tan, T.W.; August, J.T. Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLOS ONE 2007, 2, e1190.
52. Tekamp, P.A.; Penhoet, E.E. Quantification of influenza virus messenger RNAs. J Gen Virol. 1980, 47, 449–459.
53. Osterholm, M.T.; Kelley, N.S.; Sommer, A.; Belongia, E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012, 12, 36–44.
54. Lambe, T. Novel viral vectored vaccines for the prevention of influenza. Mol Med. 2012, 18, 1153–1160.
55. Barnes, E.; Folgori, A.; Capone, S.; Swadling, L.; Aston, S.; Kurioka, A.; Meyer, J.; Huddart, R.; Smith, K.; Townsend, R.; et al Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012, doi:10.1126/scitranslmed.3003155.
56. Keefer, M.C.; Gilmour, J.; Hayes, P.; Gill, D.; Kopycinski, J.; Cheeseman, H.; Cashin-Cox, M.; Naarding, M.; Clark, L.; Fernandez, N.; et al. A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLOS ONE 2012, 7, e41936.
57. Ewer, K.J.; O'Hara, G.A.; Duncan, C.J.; Collins, K.A.; Sheehy, S.H.; Reyes-Sandoval, A.; Goodman, A.L.; Edwards, N.J.; Elias, S.C.; Halstead, F.D.; et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun. 2013, doi:10.1038/ncomms3836.
58. Sheehy, S.H.; Duncan, C.J.; Elias, S.C.; Choudhary, P.; Biswas, S.; Halstead, F.D.; Collins, K.A.; Edwards, N.J.; Douglas, A.D.; Anagnostou, N.A.; et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans. Mol Ther. 2012, 20, 2355–2368.
59. Antrobus, R.D.; Berthoud, T.K.; Mullarkey, C.E.; Hoschler, K.; Coughlan, L.; Zambon, M.; Hill, A.V.; Gilbert, S.C. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol Ther. 2014, 22, 233–238.
60. Antrobus, R.D.; Coughlan, L.; Berthoud, T.K.; Dicks, M.D.; Hill, A.V.; Lambe, T.; Gilbert, S.C. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved influenza A antigens. Mol Ther. 2014, 22, 668–674.
61. Antrobus, R.D.; Lillie, P.J.; Berthoud, T.K.; Spencer, A.J.; McLaren, J.E.; Ladell, K.; Lambe, T.; Milicic, A.; Price, D.A.; Hill, A.V.; et al. A T cell-inducing influenza vaccine for the elderly: Safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLOS ONE 2012, 7, e48322.
62. Lillie, P.J.; Berthoud, T.K.; Powell, T.J.; Lambe, T.; Mullarkey, C.; Spencer, A.J.; Hamill, M.; Peng, Y.; Blais, M.E.; Duncan, C.J.; et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 2012, 55, 19–25.
63. Berthoud, T.K.; Hamill, M.; Lillie, P.J.; Hwenda, L.; Collins, K.A.; Ewer, K.J.; Milicic, A.; Poyntz, H.C.; Lambe, T.; Fletcher, H.A.; et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 2011, 52, 1–7.
64. Powell, T.J.; Peng, Y.; Berthoud, T.K.; Blais, M.E.; Lillie, P.J.; Hill, A.V.; Rowland-Jones, S.L.; McMichael, A.J.; Gilbert, S.C.; Dong, T. Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine. PLOS ONE 2013, 8, e62778.
65. Eichelberger, M.; Golding, H.; Hess, M.; Weir, J.; Subbarao, K.; Luke, C.J. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10–11, 2007. Vaccine 2008, 26, 4299–4303.
66. Grohskopf, L.A.; Shay, D.K.; Shimabukuro, T.T.; Sokolow, L.Z.; Keitel, W.A.; Bresee, J.S.; Bresee, N.J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2013–2014. Available online: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6207a1.htm (accessed on 10 February 2015)
67. Nichol, K.L.; Mallon, K.P.; Mendelman, P.M. Cost benefit of influenza vaccination in healthy, working adults: An economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003, 21, 2207–2217.
68. Remick, D.G.; Newcomb, D.E.; Friedland, J.S. Whole-blood assays for cytokine production. Methods Mol Med. 2000, 36, 101–112.
69. Calarota, S.A.; Baldanti, F. Enumeration and characterization of human memory T cells by enzyme-linked immunospot assays. Clin Dev Immunol. 2013, doi:10.1155/2013/637649.
70. Seder, R.A.; Darrah, P.A.; Roederer, M. T-cell quality in memory and protection: Implications for vaccine design. Nat Rev Immunol. 2008, 8, 247–258.
71. Leng, S.X.; McElhaney, J.E.; Walston, J.D.; Xie, D.; Fedarko, N.S.; Kuchel, G.A. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci. 2008, 63, 879–884.
72. Czerkinsky, C.C.; Nilsson, L.A.; Nygren, H.; Ouchterlony, O.; Tarkowski, A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983, 65, 109–121.
73. Zhang, W.; Caspell, R.; Karulin, A.Y.; Ahmad, M.; Haicheur, N.; Abdelsalam, A.; Johannesen, K.; Vignard, V.; Dudzik, P.; Georgakopoulou, K.; et al. ELISPOT assays provide reproducible esults among different laboratories for T-cell immune monitoring—Even in hands of ELISPOT-inexperienced investigators. J Immunotoxicol. 2009, 6, 227–234.
74. Karlsson, A.C.; Martin, J.N.; Younger, S.R.; Bredt, B.M.; Epling, L.; Ronquillo, R.; Varma, A.; Deeks, S.G.; McCune, J.M.; Nixon, D.F.; et al. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J Immunol Methods 2003, 283, 141–153.
75. Currier, J.R.; Kuta, E.G.; Turk, E.; Earhart, L.B.; Loomis-Price, L.; Janetzki, S.; Ferrari, G.; Birx, D.L.; Cox, J.H. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002, 260, 157–172.
76. Smith, J.G.; Liu, X.; Kaufhold, R.M.; Clair, J.; Caulfield, M.J. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol. 2001, 8, 871–879.
77. Palzer, S.; Bailey, T.; Hartnett, C.; Grant, A.; Tsang, M.; Kalyuzhny, A.E. Simultaneous detection of multiple cytokines in ELISPOT assays. Methods Mol Biol. 2005, 302, 273–288.
78. Gazagne, A.; Claret, E.; Wijdenes, J.; Yssel, H.; Bousquet, F.; Levy, E.; Vielh, P.; Scotte, F.; Goupil, T.L.; Fridman, W.H.; et al. A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines. J Immunol Methods 2003, 283, 91–98.
79. Todryk, S.M.; Pathan, A.A.; Keating, S.; Porter, D.W.; Berthoud, T.; Thompson, F.; Klenerman, P.; Hill, A.V. The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming. Immunology 2009, 128, 83–91.
80. Todryk, S.M.; Bejon, P.; Mwangi, T.; Plebanski, M.; Urban, B.; Marsh, K.; Hill, A.V.; Flanagan, K.L. Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans. PLOS ONE 2008, 3, e2027.
81. Keating, S.M.; Bejon, P.; Berthoud, T.; Vuola, J.M.; Todryk, S.; Webster, D.P.; Dunachie, S.J.; Moorthy, V.S.; McConkey, S.J.; Gilbert, S.C.; et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol. 2005, 175, 5675–5680.
82. Goletti, D.; Butera, O.; Bizzoni, F.; Casetti, R.; Girardi, E.; Poccia, F. Region of difference 1 antigen-specific CD4+ memory T cells correlate with a favorable outcome of tuberculosis. J Infect Dis. 2006, 194, 984–992.
83. Calarota, S.A.; Foli, A.; Maserati, R.; Baldanti, F.; Paolucci, S.; Young, M.A.; Tsoukas, C.M.; Lisziewicz, J.; Lori, F. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol 2008, 180, 5907–5915.
84. Klenerman, P.; Cerundolo, V.; Dunbar, P.R. Tracking T cells with tetramers: new tales from new tools. Nat Rev Immunol. 2002, 2, 263–272.
85. Vollers, S.S.; Stern, L.J. Class II major histocompatibility complex tetramer staining: Progress, problems, and prospects. Immunology 2008, 123, 305–313.
86. Dunbar, P.R.; Ogg, G.S.; Chen, J.; Rust, N.; van der Bruggen, P.; Cerundolo, V. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr Biol. 1998, 8, 413–416.
87. Gotch, F.; Rothbard, J.; Howland, K.; Townsend, A.; McMichael, A. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature 1987, 326, 881–882.
88. Maecker, H.T.; Hassler, J.; Payne, J.K.; Summers, A.; Comatas, K.; Ghanayem, M.; Morse, M.A.; Clay, T.M.; Lyerly, H.K.; Bhatia, S.; et al. Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol. 2008, doi:10.1186/1471-2172-9-9.
89. Tan, P.T.; Heiny, A.T.; Miotto, O.; Salmon, J.; Marques, E.T.; Lemonnier, F.; August, J.T. Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines. PLOS ONE 2010, 5, e8754.
90. Tan, P.T.; Khan, A.M.; August, J.T. Highly conserved influenza A sequences as T cell epitopes-based vaccine targets to address the viral variability. Hum Vaccin. 2011, 7, 402–409.
91. Moise, L.; Terry, F.; Ardito, M.; Tassone, R.; Latimer, H.; Boyle, C.; Martin, W.D.; de Groot, A.S. Universal H1N1 influenza vaccine development: identification of consensus class II hemagglutinin and neuraminidase epitopes derived from strains circulating between 1980 and 2011. Hum Vaccin Immunother. 2013, 9, 1598–1607.
92. Nepom, G.T. MHC class II tetramers. J Immunol. 2012, 188, 2477–2482.
93. Suni, M.A.; Picker, L.J.; Maino, V.C. Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry. J Immunol Methods 1998, 212, 89–98.
94. Nomura, L.E.; Walker, J.M.; Maecker, H.T. Optimization of whole blood antigen-specific cytokine assays for CD4+ T cells. Cytometry 2000, 40, 60–68.
95. Mittrucker, H.W.; Visekruna, A.; Huber, M. Heterogeneity in the differentiation and function of CD8+ T cells. Arch. Immunol. Ther Exp (Warsz) 2014, 62, 449–458.
96. Zhu, J.; Yamane, H.; Paul, W.E. Differentiation of effector CD4 T cell populations (*). Annu. Rev Immunol. 2010, 28, 445–489.
97. Zhou, L.; Chong, M.M.; Littman, D.R. Plasticity of CD4+ T cell lineage differentiation. Immunity 2009, 30, 646–655.
98. Boyton, R.J.; Altmann, D.M. Is selection for TCR affinity a factor in cytokine polarization? Trends Immunol. 2002, 23, 526–529.
99. Schroder, K.; Hertzog, P.J.; Ravasi, T.; Hume, D.A. Interferon-gamma: An overview of signals, mechanisms and functions. J Leukoc Biol. 2004, 75, 163–189.
100. Ciuffreda, D.; Comte, D.; Cavassini, M.; Giostra, E.; Buhler, L.; Perruchoud, M.; Heim, M.H.; Battegay, M.; Genne, D.; Mulhaupt, B.; et al. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol 2008, 38, 2665–2677.
101. Kannanganat, S.; Kapogiannis, B.G.; Ibegbu, C.; Chennareddi, L.; Goepfert, P.; Robinson, H.L.; Lennox, J.; Amara, R.R. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J Virol. 2007, 81, 12071–12076.
102. Darrah, P.A.; Patel, D.T.; de Luca, P.M.; Lindsay, R.W.; Davey, D.F.; Flynn, B.J.; Hoff, S.T.; Andersen, P.; Reed, S.G.; Morris, S.L.; et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med. 2007, 13, 843–850.
103. Precopio, M.L.; Betts, M.R.; Parrino, J.; Price, D.A.; Gostick, E.; Ambrozak, D.R.; Asher, T.E.; Douek, D.C.; Harari, A.; Pantaleo, G.; et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8+ T cell responses. J Exp Med 2007, 204, 1405–1416.
104. Beveridge, N.E.; Price, D.A.; Casazza, J.P.; Pathan, A.A.; Sander, C.R.; Asher, T.E.; Ambrozak, D.R.; Precopio, M.L.; Scheinberg, P.; Alder, N.C.; et al. Immunisation with BCG and recombinant MVA85A induces long-lasting, polyfunctional Mycobacterium tuberculosis-specific CD4+ memory T lymphocyte populations. Eur J Immunol 2007, 37, 3089–3100.
105. Qiu, Z.; Zhang, M.; Zhu, Y.; Zheng, F.; Lu, P.; Liu, H.; Graner, M.W.; Zhou, B.; Chen, X. Multifunctional CD4 T cell responses in patients with active tuberculosis. Sci Rep, 2012, doi:10.1038/srep00216.
106. Shey, M.S.; Hughes, E.J.; de Kock, M.; Barnard, C.; Stone, L.; Kollmann, T.R.; Hanekom, W.A.; Scriba, T.J. Optimization of a whole blood intracellular cytokine assay for measuring innate cell responses to mycobacteria. J Immunol Methods 2012, 376, 79–88.
107. Hanekom, W.A.; Hughes, J.; Mavinkurve, M.; Mendillo, M.; Watkins, M.; Gamieldien, H.; Gelderbloem, S.J.; Sidibana, M.; Mansoor, N.; Davids, V.; et al. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J Immunol Methods 2004, 291, 185–195.
108. Hornef, M.W.; Wagner, H.J.; Kruse, A.; Kirchner, H. Cytokine production in a whole-blood assay after Epstein-Barr virus infection in vivo. Clin Diagn Lab Immunol. 1995, 2, 209–213.
109. Meddows-Taylor, S.; Shalekoff, S.; Kuhn, L.; Gray, G.E.; Tiemessen, C.T. Development of a whole blood intracellular cytokine staining assay for mapping CD4+ and CD8+ T-cell responses across the HIV-1 genome. J Virol Methods 2007, 144, 115–121.
110. Stoddard, M.B.; Pinto, V.; Keiser, P.B.; Zollinger, W. Evaluation of a whole-blood cytokine release assay for use in measuring endotoxin activity of group B Neisseria meningitidis vaccines made from lipid A acylation mutants. Clin Vaccine Immunol. 2010, 17, 98–107.
111. Waldrop, S.L.; Davis, K.A.; Maino, V.C.; Picker, L.J. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol. 1998, 161, 5284–5295.
112. Salic, A.; Mitchison, T.J. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA 2008, 105, 2415–2420.
113. Buck, S.B.; Bradford, J.; Gee, K.R.; Agnew, B.J.; Clarke, S.T.; Salic, A. Detection of S-phase cell cycle progression using 5-ethynyl-2'-deoxyuridine incorporation with click chemistry, an alternative to using 5-bromo-2'-deoxyuridine antibodies. Biotechniques 2008, 44, 927–929.
114. Bradford, J.A.; Clarke, S.T. Dual-pulse labeling using 5-ethynyl-2'-deoxyuridine (EdU) and 5-bromo-2'-deoxyuridine (BrdU) in flow cytometry. Curr Protoc Cytom 2011, doi:10.1002/0471142956.cy0738s55.
115. Brunner, K.T.; Mauel, J.; Cerottini, J.C.; Chapuis, B. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs. Immunology 1968, 14, 181–196.
116. Zaritskaya, L.; Shurin, M.R.; Sayers, T.J.; Malyguine, A.M. New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev Vaccines 2010, 9, 601–616.
117. Sepp, A.; Binns, R.M.; Lechler, R.I. Improved protocol for colorimetric detection of complement-mediated cytotoxicity based on the measurement of cytoplasmic lactate dehydrogenase activity. J Immunol Methods 1996, 196, 175–180.
118. Szekeres, J.; Pacsa, A.S.; Pejtsik, B. Measurement of lymphocyte cytotoxicity by assessing endogenous alkaline phosphatase activity of the target cells. J Immunol Methods 1981, 40, 151–154.
119. Roden, M.M.; Lee, K.H.; Panelli, M.C.; Marincola, F.M. A novel cytolysis assay using fluorescent labeling and quantitative fluorescent scanning technology. J Immunol Methods 1999, 226, 29–41.
120. Van Baalen, C.A.; Gruters, R.A.; Berkhoff, E.G.; Osterhaus, A.D.; Rimmelzwaan, G.F. FATT-CTL assay for detection of antigen-specific cell-mediated cytotoxicity. Cytometry A 2008, 73, 1058–1065.
121. Goldberg, J.E.; Sherwood, S.W.; Clayberger, C. A novel method for measuring CTL and NK cell-mediated cytotoxicity using annexin V and two-color flow cytometry. J Immunol Methods 1999, 224, 1–9.
122. Jerome, K.R.; Sloan, D.D.; Aubert, M. Measurement of CTL-induced cytotoxicity: The caspase 3 assay. Apoptosis 2003, 8, 563–571.
123. Lecoeur, H.; Fevrier, M.; Garcia, S.; Riviere, Y.; Gougeon, M.L. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 2001, 253, 177–187.
124. Sanchez-Ruiz, Y.; Valitutti, S.; Dupre, L. Stepwise maturation of lytic granules during differentiation and activation of human CD8+ T lymphocytes. PLOS ONE 2011, 6, e27057.
125. Peters, P.J.; Borst, J.; Oorschot, V.; Fukuda, M.; Krahenbuhl, O.; Tschopp, J.; Slot, J.W.; Geuze, H.J. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med. 1991, 173, 1099–1109.
126. Fruh, K.; Simmen, K.; Luukkonen, B.G.; Bell, Y.C.; Ghazal, P. Virogenomics: A novel approach to antiviral drug discovery. Drug Discov Today 2001, 6, 621–627.
127. Bucasas, K.L.; Franco, L.M.; Shaw, C.A.; Bray, M.S.; Wells, J.M.; Nino, D.; Arden, N.; Quarles, J.M.; Couch, R.B.; Belmont, J.W. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis. 2011, 203, 921–929.
128. Woods, C.W.; McClain, M.T.; Chen, M.; Zaas, A.K.; Nicholson, B.P.; Varkey, J.; Veldman, T.; Kingsmore, S.F.; Huang, Y.; Lambkin-Williams, R.; et al. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLOS ONE 2013, 8, e52198.
129. Davenport, E.E.; Antrobus, R.D.; Lillie, P.J.; Gilbert, S.; Knight, J.C. Transcriptomic profiling facilitates classification of response to influenza challenge. J Mol Med (Berl) 2015, 93, 105–114.
130. Huang, Y.; Zaas, A.K.; Rao, A.; Dobigeon, N.; Woolf, P.J.; Veldman, T.; Oien, N.C.; McClain, M.T.; Varkey, J.B.; Nicholson, B.; et al. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza a infection. PLOS Genet. 2011, 7, e1002234.
131. Pritchard, C.C.; Cheng, H.H.; Tewari, M. MicroRNA profiling: Approaches and considerations. Nat Rev Genet 2012, 13, 358–369.
132. Liu, Z.P.; Wu, H.; Zhu, J.; Miao, H. Systematic identification of transcriptional and post-transcriptional regulations in human respiratory epithelial cells during influenza A virus infection. BMC Bioinform. 2014, doi:10.1186/1471-2105-15-336.
133. Loveday, E.K.; Svinti, V.; Diederich, S.; Pasick, J.; Jean, F. Temporal- and strain-specific host microRNA molecular signatures associated with swine-origin H1N1 and avian-origin H7N7 influenza A virus infection. J Virol. 2012, 86, 6109–6122.
134. Skovgaard, K.; Cirera, S.; Vasby, D.; Podolska, A.; Breum, S.O.; Durrwald, R.; Schlegel, M.; Heegaard, P.M. Expression of innate immune genes, proteins and microRNAs in lung tissue of pigs infected experimentally with influenza virus (H1N2). Innate Immun. 2013, 19, 531–544.
135. Tambyah, P.A.; Sepramaniam, S.; Mohamed Ali, J.; Chai, S.C.; Swaminathan, P.; Armugam, A.; Jeyaseelan, K. microRNAs in circulation are altered in response to influenza A virus infection in humans. PLOS ONE 2013, 8, e76811.
136. Satti, I.; Meyer, J.; Harris, S.A.; Manjaly Thomas, Z.R.; Griffiths, K.; Antrobus, R.D.; Rowland, R.; Ramon, R.L.; Smith, M.; Sheehan, S.; et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial. Lancet Infect Dis. 2014, 14, 939–946.
137. Sarzotti-Kelsoe, M.; Needham, L.K.; Rountree, W.; Bainbridge, J.; Gray, C.M.; Fiscus, S.A.; Ferrari, G.; Stevens, W.S.; Stager, S.L.; Binz, W.; et al. The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells. J Immunol Methods 2014, 409, 21–30.
138. Ducar, C.; Smith, D.; Pinzon, C.; Stirewalt, M.; Cooper, C.; McElrath, M.J.; Hural, J.; N.H.V.T. Network. Benefits of a comprehensive quality program for cryopreserved PBMC covering 28 clinical trials sites utilizing an integrated, analytical web-based portal. J Immunol Methods 2014, 409, 9–20.
139. Sambor, A.; Garcia, A.; Berrong, M.; Pickeral, J.; Brown, S.; Rountree, W.; Sanchez, A.; Pollara, J.; Frahm, N.; Keinonen, S.; et al. Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials. J Immunol Methods 2014, 409, 107–116.
140. Boaz, M.J.; Hayes, P.; Tarragona, T.; Seamons, L.; Cooper, A.; Birungi, J.; Kitandwe, P.; Semaganda, A.; Kaleebu, P.; Stevens, G.; et al. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents. Clin Vaccine Immunol. 2009, 16, 147–155.